Losartan

Educational clinical summary of Losartan for doctors and students: definition, workup, management, and key caveats. Not a substitute for guidelines.

Maintained by Dr. Vivek Karn Review process: editorial policy

Disclaimer: This document provides comprehensive medical information for educational and reference purposes only. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Clinicians must exercise their independent medical judgment when making patient care decisions, considering the individual patient's circumstances, clinical presentation, and current best evidence. Always consult with a qualified healthcare professional for any medical concerns or before making any decisions related to patient care. Drug dosages and indications may change, and it is the responsibility of the prescribing clinician to verify current guidelines and product information.

Losartan

Overview

Definition: Losartan is an angiotensin II receptor blocker (ARB) used primarily in the management of hypertension, heart failure, and diabetic nephropathy. It selectively blocks the binding of angiotensin II to the AT1 receptor, thereby preventing its vasoconstrictor and aldosterone-secreting effects.
Epidemiology: Losartan is indicated for conditions with high global prevalence:
- Hypertension: Affects approximately one-third of adults worldwide. ARBs, including losartan, are widely prescribed first-line or second-line agents.
- Heart Failure: A growing public health problem, with prevalence increasing with age. ARBs are a cornerstone of therapy, particularly for patients intolerant to ACE inhibitors.
- Diabetic Nephropathy: A common and serious complication of diabetes, affecting 20-40% of patients with diabetes. Losartan has demonstrated significant renoprotective effects in this population.
Classification: Losartan is classified as an Angiotensin II Receptor Blocker (ARB), specifically an AT1 receptor antagonist. It is a non-peptide tetrazole derivative.

Pathophysiology

Mechanism: Losartan's primary mechanism of action involves highly selective antagonism of the angiotensin II type 1 (AT1) receptor. Angiotensin II, a potent octapeptide hormone of the Renin-Angiotensin-Aldosterone System (RAAS), exerts various physiological effects through binding to AT1 receptors, including:
- Vasoconstriction: Directly increases systemic vascular resistance.
- Aldosterone release: Promotes sodium and water retention by the kidneys, increasing blood volume.
- Sympathetic nervous system activation: Enhances norepinephrine release.
- Cell growth and proliferation: Contributes to vascular and cardiac remodeling (e.g., hypertrophy, fibrosis).
- Renal effects: Induces efferent arteriolar constriction, increasing intraglomerular pressure. Losartan, by competitively blocking AT1 receptors, inhibits these detrimental effects, leading to:
- Vasodilation: Decreases systemic vascular resistance and blood pressure.
- Reduced aldosterone secretion: Promotes natriuresis and diuresis, reducing blood volume.
- Decreased cardiac and vascular remodeling: Attenuates fibrosis and hypertrophy.
- Reduced intraglomerular pressure: Protects the kidney from damage in certain conditions (e.g., diabetes). Losartan is a prodrug; it undergoes hepatic metabolism to an active carboxylic acid metabolite, E-3174 (also known as EXP-3174), which contributes significantly to its pharmacologic activity and has a longer half-life.
Risk Factors: (For conditions treated by Losartan)
- Hypertension: Age, obesity, unhealthy diet (high sodium, low potassium), physical inactivity, excessive alcohol intake, family history, stress, certain chronic diseases (e.g., diabetes, CKD).
- Heart Failure: Ischemic heart disease, hypertension, diabetes, obesity, valvular heart disease, cardiomyopathy, myocarditis, prolonged alcohol abuse.
- Diabetic Nephropathy: Poor glycemic control, long duration of diabetes, hypertension, dyslipidemia, genetic predisposition, smoking.
Protective Factors: (Benefits/Protective Effects of Losartan)
- Cardioprotective: Reduces cardiac hypertrophy, improves left ventricular function in heart failure, reduces risk of cardiovascular events (MI, stroke) in hypertensive patients and those with left ventricular hypertrophy.
- Renoprotective: Slows the progression of renal disease in patients with type 2 diabetes and nephropathy, by reducing proteinuria and intraglomerular pressure.
- Reduced risk of new-onset diabetes: Some evidence suggests ARBs may reduce the incidence of new-onset diabetes in hypertensive patients.
- Lower incidence of cough and angioedema: Compared to ACE inhibitors, due to not affecting bradykinin metabolism.

Clinical Presentation (Adverse Effects & Indications)

Signs and Symptoms (Adverse Effects)

Cardinal Features:
- Dizziness/Lightheadedness: Often related to orthostatic hypotension, especially at initiation or with dose escalation.
- Fatigue: Non-specific, may be related to blood pressure reduction.
- Hyperkalemia: Muscle weakness, fatigue, paresthesias, palpitations, or asymptomatic (often detected on labs).
- Renal dysfunction: Elevation in serum creatinine, often asymptomatic; can be acute or progressive.
Early Signs:
- Mild dizziness or fatigue.
- Orthostatic symptoms (e.g., lightheadedness on standing).
- Mild increase in serum creatinine or potassium from baseline.
Advanced Signs:
- Symptomatic hypotension: Syncope, severe dizziness, altered mental status.
- Severe hyperkalemia: Cardiac arrhythmias (e.g., bradycardia, widened QRS, peaked T waves), muscle paralysis.
- Acute Kidney Injury (AKI): Significant, rapid rise in serum creatinine, oliguria, uremic symptoms.
- Angioedema: Swelling of face, lips, tongue, glottis, larynx, potentially leading to airway obstruction (rare with ARBs, but possible, especially in patients with prior ACE inhibitor-induced angioedema).
Atypical Presentations:
- Cough: While less common than with ACE inhibitors, a dry cough can rarely occur.
- Rhabdomyolysis: Extremely rare, but reported, especially in combination with other drugs (e.g., statins).
- Hepatotoxicity: Very rare, but liver enzyme elevations or jaundice can occur.

Physical Examination

Inspection:
- General: Assess for signs of volume depletion (e.g., dry mucous membranes, sunken eyes) if hypotension is suspected.
- Angioedema: Swelling of face, lips, tongue, periorbital area; assess for stridor or respiratory distress if airway involvement is suspected.
Palpation:
- Pulse: Check for bradycardia (hyperkalemia) or tachycardia (hypotension).
- Blood Pressure: Measure supine and standing (orthostatic vital signs) to detect hypotension.
- Peripheral Edema: May be present in heart failure, but Losartan typically reduces, not causes, edema.
Special Tests:
- Orthostatic Vital Signs: Crucial at baseline and during dose titration, especially in elderly or volume-depleted patients. A decrease in systolic BP ≥ 20 mmHg or diastolic BP ≥ 10 mmHg within 3 minutes of standing from a supine position is indicative of orthostatic hypotension.

Diagnostic Approach (Monitoring)

History Taking

Key Questions:
- Prior medication history: Any previous intolerance to ACE inhibitors (especially cough or angioedema)?
- Comorbidities: History of renal disease, heart failure, diabetes, liver disease, bilateral renal artery stenosis (contraindication).
- Current medications: Concurrent use of NSAIDs, potassium-sparing diuretics, potassium supplements, lithium, other antihypertensives.
- Volume status: Recent vomiting, diarrhea, diuretic use, low sodium diet.
- Symptoms: Dizziness, lightheadedness, syncope, fatigue, muscle weakness, palpitations, swelling of face/lips/tongue.
- Adherence: Assess patient's understanding and compliance with medication regimen.
Red Flags:
- History of angioedema (especially severe) with previous ACE inhibitors or ARBs.
- Pregnancy or planning pregnancy.
- Bilateral renal artery stenosis (relative contraindication due to high risk of acute renal failure).
- Hyperkalemia at baseline (K+ > 5.5 mEq/L).
- Severe symptomatic hypotension.
- Rapidly worsening renal function after initiation.

Laboratory Tests

First-Line (Baseline):
- Serum Electrolytes: Sodium, potassium (K+). Baseline K+ is crucial (normal range 3.5-5.0 mEq/L); monitor for hyperkalemia.
- Renal Function Tests: Serum creatinine (SCr), blood urea nitrogen (BUN), and estimated Glomerular Filtration Rate (eGFR). Baseline assessment is essential to identify pre-existing renal impairment.
Confirmatory: Not applicable as Losartan is a treatment, not a diagnostic agent.
Monitoring (Follow-up):
- Serum Electrolytes (K+): Recheck 1-2 weeks after initiation or dose escalation, and periodically thereafter (e.g., every 1-3 months, then 6-12 months, or more frequently if risk factors for hyperkalemia exist, such as CKD, diabetes, or concomitant potassium-sparing drugs).
- Renal Function Tests (SCr, eGFR): Recheck 1-2 weeks after initiation or dose escalation, and periodically thereafter. A transient increase in SCr (up to 30% from baseline) without significant decline in GFR is often acceptable and reflects the drug's hemodynamic effect; however, a larger or progressive increase warrants investigation and potential dose adjustment/discontinuation.
- Urinalysis/Urine Albumin-to-Creatinine Ratio (UACR): Periodically monitor, especially in diabetic nephropathy or other proteinuric kidney diseases, to assess treatment efficacy in reducing proteinuria.

Imaging

Recommended: Not directly recommended for monitoring Losartan therapy itself. However, imaging may be indicated for the underlying conditions:
- Renal Duplex Ultrasound: If bilateral renal artery stenosis is suspected (e.g., in patients with refractory hypertension, AKI upon RAAS inhibitor initiation, or asymmetric kidney size). This is generally done before starting Losartan if concerns exist.
- Echocardiogram: For assessing cardiac function in heart failure patients or those with left ventricular hypertrophy.
Advanced: N/A for Losartan specific monitoring.

Management

Acute Management (of Losartan-related adverse effects)

Immediate:
- Symptomatic Hypotension: Immediately stop losartan. Place patient supine, elevate legs. Assess vital signs and hydration status.
- Angioedema: Secure airway (intubation may be required for laryngeal edema). Administer epinephrine if severe and rapidly progressing.
- Severe Hyperkalemia (K+ > 6.5 mEq/L or with ECG changes): Discontinue Losartan. Initiate emergency hyperkalemia protocol (e.g., IV calcium gluconate for cardiac membrane stabilization, IV insulin with glucose, albuterol nebulization, IV furosemide, sodium polystyrene sulfonate or patiromer/sodium zirconium cyclosilicate if not urgent).
- Acute Kidney Injury: Stop Losartan. Assess for other causes (e.g., volume depletion, other nephrotoxic drugs, bilateral renal artery stenosis).
Stabilization:
- Hypotension: IV fluid bolus (e.g., 250-500 mL normal saline) if volume depleted. Consider vasopressors if refractory.
- Angioedema: Observe closely in a monitored setting. Corticosteroids and antihistamines are often administered, though their efficacy for ARB-induced angioedema is limited.
Emergency:
- Airway obstruction due to angioedema: Emergency intubation or tracheostomy.
- Life-threatening arrhythmias due to hyperkalemia: Advanced cardiac life support (ACLS) protocol.
- Severe AKI with uremic symptoms/fluid overload/refractory hyperkalemia: Dialysis may be required.

Chronic Management (Pharmacological)

Pharmacological: Losartan is available as oral tablets.
- Indications and Dosing:
  - Hypertension (HTN):
    - Initial Dose: 50 mg orally once daily. May start with 25 mg once daily in patients with possible volume depletion or hepatic impairment.
    - Maintenance Dose: 25 mg to 100 mg orally once daily.
    - Titration: Dose can be increased after 3-6 weeks if BP control is inadequate.
    - Maximum Dose: 100 mg orally once daily.
  - Heart Failure (HF) (in patients intolerant to ACE inhibitors):
    - Initial Dose: 12.5 mg orally once daily.
    - Maintenance Dose: Gradually titrate to a target dose of 50 mg orally once daily, as tolerated.
    - Titration: Double the dose at weekly intervals, as tolerated.
  - Diabetic Nephropathy (Type 2 Diabetes with Proteinuria):
    - Initial Dose: 50 mg orally once daily.
    - Maintenance Dose: The dose should be increased to 100 mg orally once daily based on blood pressure response.
    - Target: The RENAAL study used a target dose of 100 mg/day for renoprotection.
- Special Considerations:
  - Hepatic Impairment: Consider lower starting dose (25 mg) due to increased plasma concentrations of Losartan and its active metabolite.
  - Renal Impairment: No initial dose adjustment generally required, but close monitoring of renal function and potassium is essential.
  - Volume Depletion: Correct volume depletion prior to initiation or start with a lower dose.
- Drug Interactions:
  - Potassium-Sparing Diuretics (e.g., spironolactone, amiloride, triamterene), Potassium Supplements, Salt Substitutes (containing potassium): Increased risk of hyperkalemia. Avoid concomitant use or monitor potassium very closely.
  - NSAIDs (Nonsteroidal Anti-inflammatory Drugs): Can attenuate the antihypertensive effect of Losartan and increase the risk of renal dysfunction, especially in elderly or volume-depleted patients, or those with pre-existing renal impairment. Avoid concomitant use or monitor renal function closely.
  - Lithium: Losartan can reduce renal clearance of lithium, leading to increased lithium levels and toxicity. Monitor lithium levels closely if co-administered.
  - Dual RAAS Blockade (e.g., with ACE inhibitors or direct renin inhibitors like aliskiren): Generally not recommended due to increased risk of hyperkalemia, hypotension, and renal impairment without significant additional cardiovascular benefit. Especially contraindicated with aliskiren in diabetic or renal-impaired patients.
- Contraindications:
  - Hypersensitivity to Losartan or any component of the formulation.
  - Pregnancy (Category D): Can cause fetal harm or death. Discontinue as soon as pregnancy is detected.
  - Concomitant use with aliskiren in patients with diabetes or moderate to severe renal impairment (eGFR < 60 mL/min/1.73m²).
Non-pharmacological: (Complementary to Losartan therapy)
- Dietary Modifications:
  - DASH diet: Emphasizes fruits, vegetables, whole grains, lean protein, and low-fat dairy.
  - Sodium restriction: Limit intake to < 2.3 g/day (or < 1.5 g/day for higher benefit/risk).
  - Potassium-rich foods: Encourage intake of fruits and vegetables (unless hyperkalemia is an issue).
- Lifestyle Modifications:
  - Regular physical activity: At least 150 minutes of moderate-intensity aerobic activity per week.
  - Weight management: Maintain a healthy BMI (18.5-24.9 kg/m²).
  - Alcohol moderation: Limit to ≤ 2 drinks/day for men and ≤ 1 drink/day for women.
  - Smoking cessation.
  - Stress reduction techniques.
Monitoring (Chronic):
- Blood Pressure: Regularly measure BP to assess efficacy and guide titration. Home BP monitoring is encouraged.
- Renal Function (SCr, eGFR): Periodically (e.g., every 3-6 months, or as clinically indicated). A small, stable increase in SCr is often acceptable. Discontinue if SCr increases by > 30% from baseline, or if symptoms of renal impairment develop, and investigate alternative causes.
- Serum Potassium (K+): Periodically (e.g., every 3-6 months, or as clinically indicated), especially in patients with CKD, diabetes, or those on potassium-sparing drugs. Aim for K+ < 5.5 mEq/L.

Treatment Algorithms

First-Line:
- Hypertension: Losartan is a recommended first-line agent for essential hypertension, particularly in patients who cannot tolerate ACE inhibitors (e.g., due to cough). It is also preferred in hypertensive patients with compelling indications like diabetic nephropathy or heart failure.
- Diabetic Nephropathy: Losartan (100 mg/day) is a first-line therapy for renoprotection in patients with type 2 diabetes and evidence of nephropathy (e.g., albuminuria).
- Heart Failure with Reduced Ejection Fraction (HFrEF): While ACE inhibitors are generally preferred first-line, Losartan is a recommended alternative for patients with HFrEF who are intolerant to ACE inhibitors.
Second-Line:
- In hypertension, Losartan can be used as a second-line agent in combination with other classes of antihypertensives (e.g., diuretics, calcium channel blockers) if monotherapy is insufficient.
Refractory Cases:
- If Losartan monotherapy does not achieve target blood pressure, it should be combined with other antihypertensive agents from different classes (e.g., a thiazide diuretic, calcium channel blocker).
- For heart failure or diabetic nephropathy, ensure maximum tolerated doses of evidence-based therapies are used. Consider referral to a specialist (e.g., cardiologist, nephrologist).
- Investigate secondary causes of hypertension or resistant heart failure.

Complications (Adverse Effects)

Common:
- Dizziness, lightheadedness (especially orthostatic hypotension).
- Fatigue.
- Hyperkalemia (mild).
- Renal dysfunction (mild, transient increase in SCr).
- Nausea, diarrhea, dyspepsia.
- Upper respiratory tract infection, cough (less common than with ACE inhibitors).
Serious:
- Angioedema: Although rare, it can be life-threatening if it involves the larynx/airway. Incidence is lower than with ACE inhibitors but higher in patients with a history of ACE inhibitor-induced angioedema.
- Severe Hypotension: Especially in volume-depleted patients or those with severe heart failure.
- Acute Kidney Injury (AKI): Particularly in patients with bilateral renal artery stenosis, severe heart failure, or volume depletion.
- Severe Hyperkalemia: Can lead to life-threatening cardiac arrhythmias.
- Fetal Toxicity: Teratogenic, causes significant fetal morbidity and mortality.
- Anaphylaxis: Extremely rare.
Long-term:
- No specific long-term adverse effects unique to Losartan beyond those listed. The long-term benefits are prevention of cardiovascular and renal complications associated with the underlying diseases.

Prognosis

Factors (influenced by Losartan):
- Hypertension: Losartan significantly reduces blood pressure, which is a primary determinant of cardiovascular risk. Effective BP control reduces the risk of stroke, myocardial infarction, heart failure, and renal disease.
- Heart Failure: In patients with HFrEF intolerant to ACE inhibitors, Losartan (e.g., LIFE study, ELITE II) has been shown to reduce mortality and morbidity, improve symptoms, and reduce hospitalizations. It helps mitigate detrimental cardiac remodeling.
- Diabetic Nephropathy: The RENAAL study showed Losartan significantly reduces the composite endpoint of doubling of serum creatinine, end-stage renal disease, or death in patients with type 2 diabetes and nephropathy, demonstrating its renoprotective benefits. It reduces proteinuria, which is a strong predictor of renal progression.
Survival:
- Heart Failure: Losartan improves survival in patients with HFrEF, particularly those unable to tolerate ACE inhibitors.
- Hypertension: By effectively controlling blood pressure, Losartan indirectly improves long-term survival by reducing the incidence of fatal cardiovascular events.
- Diabetic Nephropathy: Delays progression to end-stage renal disease and reduces mortality in type 2 diabetics with nephropathy.
Quality of Life:
- By controlling blood pressure, reducing heart failure symptoms, and slowing the progression of kidney disease, Losartan generally improves patients' quality of life, reduces symptoms, and decreases the burden of complications.

Prevention

Primary:
- Losartan does not prevent the occurrence of hypertension, heart failure, or diabetes. However, in patients with these conditions, Losartan serves as a primary preventative measure against their severe complications (e.g., stroke, MI, renal failure, hospitalization for HF).
Secondary:
- Hypertension: Prevents the progression of hypertension to target organ damage (e.g., left ventricular hypertrophy, renal dysfunction, atherosclerosis).
- Heart Failure: Prevents further deterioration of cardiac function and reduces the frequency of acute decompensations and hospitalizations in patients with established HF.
- Diabetic Nephropathy: Slows the progression of existing kidney disease and reduces proteinuria in patients with type 2 diabetes.
Tertiary:
- Prevents serious long-term complications and improves outcomes in patients with established cardiovascular or renal disease (e.g., preventing stroke/MI recurrence, preventing need for dialysis).

Special Populations

Pediatric:
- Use in children ≥ 6 years of age with hypertension: Initial dose typically 0.7 mg/kg once daily (max 50 mg), titrated based on BP response up to a maximum of 1.4 mg/kg (or 100 mg total). Limited data for children < 6 years or for other indications. Close monitoring of renal function and potassium is crucial.
Geriatric:
- Increased susceptibility to hypotension and hyperkalemia due to age-related changes in renal function, volume status, and comorbidities.
- Consider lower initial dose (e.g., 25 mg once daily) and slower titration, particularly in those with volume depletion or significant comorbidities.
- Closely monitor blood pressure, renal function, and serum potassium.
Pregnancy:
- Absolute Contraindication (FDA Pregnancy Category D). Losartan can cause oligohydramnios, fetal lung hypoplasia, skeletal deformities, and death, particularly when used in the second and third trimesters.
- If pregnancy is detected, Losartan should be discontinued as soon as possible. Alternative antihypertensive medications should be used.
Comorbidities:
- Renal Impairment: No initial dose adjustment for mild-moderate CKD, but close monitoring of SCr, eGFR, and K+ is essential. Use with caution in severe renal impairment. Avoid in bilateral renal artery stenosis.
- Hepatic Impairment: Consider a lower starting dose (25 mg) due to increased systemic exposure.
- Volume Depletion: Correct volume depletion (e.g., due to diuretics, vomiting, diarrhea) before initiating Losartan, or start with a very low dose, to minimize the risk of symptomatic hypotension.
- Hyperkalemia: Avoid initiation if baseline K+ > 5.5 mEq/L. If hyperkalemia develops during therapy, consider dose reduction, discontinuation, or management with potassium-lowering agents and dietary changes.

Clinical Pearls

Diagnostic:
- Always check baseline serum creatinine, eGFR, and potassium before initiating Losartan, and within 1-2 weeks of initiation or dose change.
- Transient, mild elevations in SCr (e.g., < 30% from baseline) are common and usually reflect expected hemodynamic effects; monitor, but often no intervention is needed if stable. Significant or progressive increases warrant investigation.
- Be vigilant for signs of hyperkalemia, especially in patients with diabetes, CKD, or those on potassium-sparing drugs.
Treatment:
- Losartan can be an excellent alternative to ACE inhibitors for patients who experience ACE inhibitor-induced cough, as it does not affect bradykinin metabolism.
- Start low and go slow, especially in elderly, volume-depleted, or heart failure patients.
- Encourage home blood pressure monitoring to assess treatment efficacy and guide titration.
- In diabetic nephropathy, aiming for the 100 mg/day dose is important for optimal renoprotection, provided it is tolerated.
- Counsel patients on the importance of avoiding potassium supplements and NSAIDs unless specifically advised by their clinician.
Pitfalls:
- Prescribing in pregnancy: A critical and absolute contraindication. Ensure female patients of childbearing potential are aware of the risks and use effective contraception, or switch to an alternative if pregnancy is planned or occurs.
- Concomitant use of NSAIDs: Can lead to acute kidney injury, especially in vulnerable patients (elderly, CKD, volume depleted). Advise patients to avoid over-the-counter NSAIDs.
- Unrecognized bilateral renal artery stenosis: Can precipitate severe AKI upon initiation.
- Dual RAAS blockade: Generally discouraged due to increased risk of adverse events without proven additional benefit.
- Hyperkalemia: Failure to monitor potassium levels can lead to life-threatening arrhythmias.

Recent Updates

Guidelines:
- 2017 ACC/AHA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Reaffirms ARBs as a first-line option for hypertension. Emphasizes the importance of individualized BP targets and shared decision-making.
- 2021 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure: Continue to recommend ARBs as an alternative to ACE inhibitors for HFrEF patients who are intolerant to ACE inhibitors.
- KDIGO (Kidney Disease: Improving Global Outcomes) 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease: Recommends RAAS inhibitors (ACEi or ARB) as first-line antihypertensive therapy in patients with CKD and albuminuria to reduce proteinuria and slow CKD progression.
Evidence:
- Recent meta-analyses continue to support the cardiovascular and renoprotective benefits of ARBs, including losartan, across various populations. No major paradigm shifts regarding losartan's role, reinforcing its established efficacy and safety profile.
- Ongoing research often focuses on combination therapies or personalized approaches to RAAS inhibition rather than significant changes in single-agent ARB use.
Controversies:
- Dual RAAS Blockade: While largely resolved with a strong recommendation against routine use, there are still discussions in very specific, highly selected patient groups (e.g., severe proteinuria), though not generally recommended due to safety concerns.
- Optimal Blood Pressure Targets: Ongoing debate exists for specific populations (e.g., elderly, very high risk), which may influence the intensity of Losartan titration.

Key References

Guidelines:
- Whelton PK, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018 May 15;71(19):e127-e248.
- McDonagh TA, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2021 Sep 21;42(36):3599-3726.
- Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney Int. 2021 Mar;99(3S):S1-S87.
Studies:
- LIFE Study (Losartan Intervention For Endpoint reduction in hypertension study): Dahlof B, et al. Cardiovascular morbidity and mortality in patients with essential hypertension and left ventricular hypertrophy: a randomised trial against atenolol. Lancet. 2002 Mar 23;359(9311):995-1003. (Demonstrated Losartan's superiority over atenolol in reducing cardiovascular morbidity and mortality in hypertensive patients with LVH).
- RENAAL Study (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan): Brenner BM, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001 Apr 12;345(12):861-9. (Showed Losartan reduced the primary composite endpoint of doubling of serum creatinine, end-stage renal disease, or death in type 2 diabetic patients with nephropathy).
- ELITE II Study (Evaluation of Losartan In The Elderly study II): Pitt B, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II. Lancet. 2000 Feb 5;355(9215):1582-7. (Compared losartan vs. captopril in HF, showing no significant difference in overall mortality, supporting losartan as an alternative).
Reviews:
- Various systematic reviews and meta-analyses published in journals like Cochrane Database of Systematic Reviews, Hypertension, and Journal of the American College of Cardiology on the efficacy and safety of ARBs in hypertension, heart failure, and renal disease.